PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.68M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-31.01%
Both yoy net incomes decline, with CRK at -133.98%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-23.63%
Both reduce yoy D&A, with CRK at -144.94%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-26.56%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
253.33%
SBC growth well above CRK's 12.66%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-35.14%
Both reduce yoy usage, with CRK at -54.19%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-34.13%
Both yoy AR lines negative, with CRK at -76.48%. Martin Whitman would suspect an overall sector lean approach or softer demand.
19.05%
Inventory growth of 19.05% while CRK is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
44.37%
Lower AP growth vs. CRK's 200.05%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-35.14%
Both reduce yoy usage, with CRK at -3877.41%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
124.07%
Lower 'other non-cash' growth vs. CRK's 809.50%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-22.19%
Both yoy CFO lines are negative, with CRK at -14.20%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-4.92%
Both yoy lines negative, with CRK at -0.53%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-1249.20%
Negative yoy acquisition while CRK stands at 31565.38%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
334.85%
We have some outflow growth while CRK is negative at -312.11%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-248.55%
We reduce yoy invests while CRK stands at 9.08%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
98.59%
Debt repayment growth of 98.59% while CRK is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
No Data
No Data available this quarter, please select a different quarter.
62.76%
Buyback growth of 62.76% while CRK is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.